Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8355921 | 1.00 | ALDH1A1 (0.37) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL8245109 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL2630647 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL8172288 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL13359028 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL2631450 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL8247842 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL1101712 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAATMMGAM | |
| SCHEMBL8351184 | 0.84 | ALDH1A1 (0.35) | ALDH1A1NPSR1LMNAATM | |
| SCHEMBL15461445 | 0.83 | ALDH1A1 (0.40) | ALDH1A1NPSR1LMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912999-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-05 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009080542-A1 | PROCESS FOR THE PREPARATION OF A MACROCYCLE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | ALDH1A1 3982/4885NPSR1 2149/4885LMNA 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.